Boston Scientific Receives FDA Clearance for the Asurys Fluid Management System

Key Takeaways

• FDA clears Asurys for irrigation and pressure control
• Auto-regulates intrarenal pressure during ureteroscopy
• Integrates with LithoVue Elite for on-demand flushing
• Reduces staff workload, improves procedural efficiency
• Limited US release begins within days

Summary

Boston Scientific announced FDA 510(k) clearance for its Asurys Fluid Management System, a device that provides automated irrigation and intrarenal pressure control during endoscopic urologic procedures such as ureteroscopy. The system integrates with the LithoVue Elite single‑use digital ureteroscope, allowing real‑time pressure monitoring and on‑demand flushing from the scope handle. By automatically regulating flow, Asurys aims to lower the risk of pressure‑related complications while reducing staff involvement. A limited U.S. market release is slated to begin within days.

Pulse Analysis

Kidney stones affect roughly one in ten Americans, making ureteroscopy one of the most frequently performed endoscopic procedures in urology. While the technique offers direct visualization and laser lithotripsy, surgeons must balance continuous irrigation against rising intrarenal pressure (IRP), a factor linked to postoperative sepsis, systemic inflammatory response syndrome, and renal injury. Historically, clinicians relied on manual adjustments and intermittent pressure checks, which can interrupt workflow and increase cognitive load. The lack of real‑time pressure feedback has left a gap in patient safety and procedural efficiency.

The Asurys Fluid Management System, now cleared by the FDA under a 510(k) pathway, fills that gap by automatically modulating irrigation flow based on IRP data. When paired with Boston Scientific’s LithoVue Elite single‑use digital ureteroscope, the system can receive pressure readings and adjust inflow without surgeon intervention, while also offering an on‑demand flush button on the scope handle. This closed‑loop control reduces reliance on operating‑room staff, shortens irrigation pauses, and helps maintain a clear visual field, ultimately lowering the risk of pressure‑related complications.

Boston Scientific’s limited U.S. rollout positions Asurys as a potential new benchmark for endourologic devices. By streamlining workflow and providing objective pressure management, hospitals may see shorter case times and fewer adverse events, translating into cost savings and higher patient satisfaction. The technology also extends to cystoscopy, percutaneous nephrolithotomy, and BPH surgeries, suggesting a broader market impact. If early adopters report favorable outcomes, competitors are likely to accelerate development of similar closed‑loop irrigation platforms, reshaping standards across minimally invasive urology.